Evercore ISI Downgrades Spero Therapeutics (NASDAQ:SPRO) to In-Line

Spero Therapeutics (NASDAQ:SPRO) was downgraded by research analysts at Evercore ISI from an “outperform” rating to an “in-line” rating in a research report issued to clients and investors on Friday, Marketbeat reports. They presently have a $5.00 price objective on the stock. Evercore ISI’s target price would indicate a potential upside of 401.00% from the company’s previous close.

Several other brokerages have also issued reports on SPRO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a research note on Monday, December 2nd. Finally, TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Stock Performance

Spero Therapeutics stock opened at $1.00 on Friday. Spero Therapeutics has a 52 week low of $0.99 and a 52 week high of $1.89. The firm has a market cap of $54.41 million, a P/E ratio of 14.26 and a beta of 0.59. The business’s fifty day moving average is $1.20 and its two-hundred day moving average is $1.29.

Institutional Investors Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 975,952 shares of the company’s stock after buying an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned 1.81% of Spero Therapeutics worth $1,269,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.